RAT-HEMATO : Return to Work After Malignant Hemopathy

Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.

Sex

All

Minimum age

18 Years

Maximum age

55 Years

Inclusion Criteria :

* Patient with hematological malignancy controlled after treatment
* Induction/consolidation chemotherapy completed (excluding maintenance therapy)
* Patient aged 18 to 55
* Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy
* Patient who has not yet returned to work since diagnosis of hematological malignancy
* Signed informed consent form

Exclusion Criteria:

* Patient choosing not to return to work
* Patient not affiliated to a social security system
* Patient with legal guardian or legal trustee
* Patient not understanding French
* Patient with severe cognitive impairment at diagnosis, incompatible with the study